The U.S. Food and Drug Administration has approved the antipsychotic drug Abilify (aripiprazole) for adolescents aged 13 to 17 diagnosed with schizophrenia. References and Resources
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for Adolescent Patients with Schizophrenia Click Here
for the news release.
FDA Information Sheet: Aripiprazole (marketed at Abilify) Click Here
to view FDA information.